[Rapid Idylla™ mutational testing: Current and future theranostic applications]
Amélie Bourhis1, Annabelle Remoué1, Laura Samaison2
1Service d'anatomie et cytologie pathologiques, hôpital Morvan, CHRU de Brest, 5, avenue Foch, 29609 Brest, France.
Abstract:
Molecular analyses have become mandatory for treatment choices in patients with various advanced cancers. Beside next generation sequencing (NGS) analyzing genes panels, non-NGS targeted analyses about the main biomarkers remain of interest. In this article, we review the data about the fast and fully automated real-time PCR platform Idylla™ (Biocartis, Mechelen, Belgium) permitting the mutational analyses of BRAF, KRAS, NRAS, EGFR and microsatellite instability notably in melanoma, non-small-cell lung cancer and colorectal cancer samples. Future applications as well as the implementation of Idylla™ in the workflow of pathology and/or molecular biology laboratories are also discussed.
Insights
The Idylla™ platform offers fast, automated molecular analysis for key cancer biomarkers like BRAF and EGFR. This real-time PCR technology aids treatment decisions in advanced cancers, including melanoma, lung, and colorectal cancers.
Area of Science:
- Oncology
- Molecular Diagnostics
- Biomarker Analysis
Background:
- Molecular analyses are crucial for guiding cancer treatment decisions in advanced stages.
- Next-generation sequencing (NGS) and targeted non-NGS analyses are key molecular diagnostic approaches.
- The Idylla™ platform provides rapid, automated real-time PCR for specific biomarker mutations.
Purpose of the Study:
- To review data on the Idylla™ platform for molecular analysis of cancer biomarkers.
- To evaluate the platform's utility in detecting mutations in BRAF, KRAS, NRAS, and EGFR, and microsatellite instability.
- To discuss the implementation and future applications of Idylla™ in laboratory workflows.
Main Methods:
- Review of existing data on the Idylla™ real-time PCR platform.
- Focus on automated mutational analyses of specific genes (BRAF, KRAS, NRAS, EGFR).
- Assessment of microsatellite instability detection capabilities.
Main Results:
- The Idylla™ platform enables fast and fully automated real-time PCR for targeted biomarker analysis.
- The platform is effective for analyzing key mutations in melanoma, non-small-cell lung cancer, and colorectal cancer.
- Data supports the utility of Idylla™ in molecular diagnostics for advanced cancers.
Conclusions:
- The Idylla™ platform is a valuable tool for rapid, automated molecular testing in oncology.
- Its implementation can streamline workflows in pathology and molecular biology labs.
- The platform supports critical biomarker analysis for personalized cancer treatment.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
10:57Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018